| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/09/2004 | WO2003093478A9 Immunoconjugates for the treatment of tumours |
| 12/09/2004 | WO2003062262A3 Modulation of heat-shock-protein-based immunotherapies |
| 12/09/2004 | US20040249892 Secure header information for multi-content e-mail |
| 12/09/2004 | US20040249576 Methods for rational pegylation of proteins |
| 12/09/2004 | US20040249178 Biological conjugates used for drug delivery; side effect reduction |
| 12/09/2004 | US20040249141 Tie ligand homologues |
| 12/09/2004 | US20040249135 Using high energy electromagnetic waves to destroy viral, prion, bacterial, fungal and parasitic contaminants in immunoglobulin; antibody purity and immunotherapy |
| 12/09/2004 | US20040249130 Aptamer-toxin molecules and methods for using same |
| 12/09/2004 | US20040249124 Viral protein for use in generation of immunogllobulins to prevent lymphadenopathy associated viral infections; immunotherapy; viricides |
| 12/09/2004 | US20040249082 Protein compatible methods and compounds for controlling the morphology and shrinkage of silica derived from polyol-modified silanes |
| 12/09/2004 | US20040249035 Granulate or powder for producing coating or binding agents for medicaments |
| 12/09/2004 | US20040248993 for skin care, comprising 1,5-pentanediol and a carrier, free of polysiloxane, volatile siloxane, phosphatidylcholine, creatine, carnitine, panthenol, pyruvic acid, lauric acid monoglyceride, or myristic acid monoglyceride; treating dry skin or dermatitis; patches and containers; optionally with drugs |
| 12/09/2004 | US20040248974 Self emulsifying drug delivery system |
| 12/09/2004 | US20040248966 A drug contains melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists, in an effective amount within the range of 0.0025 to 50 mg, and other therapeutic agent; improving the restorative quality of sleep; sustained release |
| 12/09/2004 | US20040248942 Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| 12/09/2004 | US20040248930 Topical composition |
| 12/09/2004 | US20040248924 Compositions for treatment of common cold |
| 12/09/2004 | US20040248901 Microemulsified with fatty acid or alcohol and surfactant; bioavailability; low cost, capsules |
| 12/09/2004 | US20040248874 Anti-microbial composition comprising a metal ion chelating agent |
| 12/09/2004 | US20040248867 Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| 12/09/2004 | US20040248866 Mometasone furoate cream in oil; stability; bioavailability ; antiinflammatory agents |
| 12/09/2004 | US20040248856 Chelating agents with lipophilic carriers |
| 12/09/2004 | US20040248847 Neutralized with dextran; adjustment of ph; prevent eye damage |
| 12/09/2004 | US20040248843 Process for the preparation of tablets comprising s-adenosylmethionine |
| 12/09/2004 | US20040248842 Complexes for transporting nucleic acid into eukaryotic higher-cells |
| 12/09/2004 | US20040248833 Therapeutic delivery compositions and methods of use thereof |
| 12/09/2004 | US20040248832 Enhancement of transfection of dna into the liver |
| 12/09/2004 | US20040248831 Oligodeoxynucleic acid modified with (thio)phosphate |
| 12/09/2004 | US20040248806 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same |
| 12/09/2004 | US20040248804 Nasal administration of the LH-RH analog Leuprolide |
| 12/09/2004 | US20040248797 Pharmaceutical compositions of erythropoietin |
| 12/09/2004 | US20040248793 Stabilised solid compositions of factor VII polypeptides |
| 12/09/2004 | US20040248792 Thymosin alpha 1 peptide/.polymer conjugates |
| 12/09/2004 | US20040248789 peptides/fusion inhibitors; |
| 12/09/2004 | US20040248783 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments |
| 12/09/2004 | US20040248782 Long lasting glucagon-like peptide2(glp-2)for the treatment of gastrointestinal diseases and disorders |
| 12/09/2004 | US20040248778 Stable galenic freeze-dried pharmaceutical preparation of recombined carbohydrate-binding polypeptides |
| 12/09/2004 | US20040248765 Tumour targeting prodrugs activated by metallo matrixproteinases |
| 12/09/2004 | US20040248326 Hydrogel compositions, devices, and microscale components |
| 12/09/2004 | US20040248320 Medical device with array of electrode-containing reservoirs |
| 12/09/2004 | US20040248078 Contacting osteoblast and osteocyte with either a glucocorticoid alone or in combination with test compound and comparing number of osteoblast and osteocyte undergoing apoptosis, lowered number of apoptotic cells indicates test compound is modulator of glucocorticoid induced osteoporosis |
| 12/09/2004 | US20040247695 Light-stabilized $I(in vivo) stain composition and method of manufacture |
| 12/09/2004 | US20040247684 Thermostable aqueous solution or gel or lyophilized powders for an implantable drug delivery device; improved heat and oxidation resistance |
| 12/09/2004 | US20040247681 An acrylated polypropylene glycol or 1,2-propylene oxide adduct copolymerized with an acrylic silyl ester or an acrylic ketone; controlled release ocular inserts; glaucoma, cataracts |
| 12/09/2004 | US20040247680 Targeted delivery of controlled release polymer systems |
| 12/09/2004 | US20040247676 The active and barrier layers each contain two or more hydrophilic polymers, a lipophilic substance, and an adjuvant; side effect reduction; single daily dosage |
| 12/09/2004 | US20040247674 Drug delivery system |
| 12/09/2004 | US20040247672 Injectable sustained release compositions |
| 12/09/2004 | US20040247666 Prompt-release formulations containing an active ingredient solubilised, suspended or embedded in an amphiphilic matrix; improved pharmacokinetics |
| 12/09/2004 | US20040247663 Liposomes with effector biomolecules attached to the distal ends of hydrophilic polymer chains provide increased time in the bloodstream; polymyxin B used for septic shock |
| 12/09/2004 | US20040247660 Protein-stabilized liposomal formulations of pharmaceutical agents |
| 12/09/2004 | US20040247659 (Ester)-lysolecithins in liposomes |
| 12/09/2004 | US20040247658 Delivery system with increased bioavailability |
| 12/09/2004 | US20040247654 A radiation curable mixture of a swellable adhesive polymer that forms a pressure sensitive adhesive, a swelling agent, and herbal medicines; transdermal drug delivery |
| 12/09/2004 | US20040247640 Nitric oxide releasing eptfe coated medical device sandwich |
| 12/09/2004 | US20040247632 Chitosan microparticles for the topical delivery of water insoluble active agents |
| 12/09/2004 | US20040247630 Cosmetic and/or pharmaceutical preparations |
| 12/09/2004 | US20040247628 Kit for the preparation of a pharmaceutical composition |
| 12/09/2004 | US20040247627 Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent |
| 12/09/2004 | US20040247625 Pharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support |
| 12/09/2004 | US20040247623 Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
| 12/09/2004 | US20040247611 Immunoassay for identifying pathogen-ligand interactions under shear conditions; vaccines containing an anti-adhesive monoclonal antibody, an adhesive peptide, or a pathogen adhesin |
| 12/09/2004 | US20040247608 The hapten moieties are attached, directly or indirectly, to lysines of the monomeric units of the carrier; particularly an aggregated STn-KLH conjugate; used particularly for cancer immunotherapy |
| 12/09/2004 | US20040247604 Anti-inflamatory fatty alcohols and fatty acid esters useful as antigen carriers |
| 12/09/2004 | US20040247589 More particularly from the serum of alligators or crocodiles; active proteins obtained from the sera show no overt toxicity in healthy mammals, and may therefore be used for the prevention, investigation, treatment or diagnosis of cancer |
| 12/09/2004 | US20040247588 Lyophilizing a solution of a modified antibody (especially Certolizumab Pegol) containing molecules capable of adversely affecting the stability or solubility of the antibody after lyophilization and from which some of those moledules have been removed |
| 12/09/2004 | US20040247569 Reduction in bacterial colonization by administering bacteriophage compositions |
| 12/09/2004 | US20040247561 Polylactic, glycolic, or mendelic acid or copolymers in which the terminal hydroxy groups have been esterified or etherified and the terminal carboxy group optionally neutralized with Li, Na or K; capable of forming micelles in an aqueous solution with a pH of 4 or more |
| 12/09/2004 | US20040247560 Improved palatability, especially masking the bitter taste of quinolone antibiotics; particle size of less than 50 mu m. delays the formation of a sediment and means that the sediment is very easy to reagitate. |
| 12/09/2004 | US20040247541 Hydrophilic ingredient such as biotin, carnitine and derivatives thereof, creatine and derivatives thereof, folic acid, pyridoxine, niacinamide, polyphenols, ascorbic acid, Hamamelis, Aloe, or panthenol containing as a photostabilizer a di(C 6-24 branched or unbranched alkyl) 2,6-naphthalenedicarboxylate |
| 12/09/2004 | US20040247537 Uv-screening peptide-flavonoid conjugates |
| 12/09/2004 | US20040247535 Contains mono-, di- or tripotassium phosphate to inactivate dental nerves to relieve temporary pains; not only prevents but blocks the exposure of dentinal tubules; may also contain ursodesoxycholic acid and a humectant such as glycerin, sorbitol , xylitol, polyethylene glycol and/or propylene glycol |
| 12/09/2004 | US20040247532 NaCl, KCl, NaHCO3, monobasic or dibasic potassium phosphate saliva substitute; triclosan, chlorhexidine or benzalkonium and salts, or cetylpyridium chloride antiseptic; NaF, Na2PO3F, or xylitol anticariogenic agent; vitamin E acetate, panthenol, dipotassium glycyrrhizinate, or aloe vera extract |
| 12/09/2004 | US20040245675 Injection molding process for the preparation of an oral delivery device for a pharmaceutically active agent |
| 12/09/2004 | US20040244794 Inhalation device with a pharmaceutical composition |
| 12/09/2004 | DE29624506U1 Oral composition for poorly soluble basic drugs and macrolide antibiotics - contains alginate complex matrix and organic acid |
| 12/09/2004 | DE102004012273A1 Stabile und geschmacksmaskierte pharmazeutische Dosierungsform unter Verwendung von porösen Apatit-Körnern Stable and taste masked pharmaceutical dosage form using porous apatite grains |
| 12/09/2004 | CA2532707A1 Novel topical steroid cream formulations |
| 12/09/2004 | CA2527722A1 Biodegradable poly(beta-amino esters) and uses thereof |
| 12/09/2004 | CA2527429A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents |
| 12/09/2004 | CA2527301A1 Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
| 12/09/2004 | CA2527109A1 Oligo double-stranded rna inhibiting the expression of bcl-2 and medicinal composition containing the same |
| 12/09/2004 | CA2525973A1 Combination chemotherapy comprising capecitabine and a liposomal platinum complex |
| 12/09/2004 | CA2524094A1 Low sodium solution |
| 12/09/2004 | CA2495270A1 Transdermal vaccine delivery device having coated microprotrusions |
| 12/08/2004 | EP1484332A2 Lipid-based drug delivery system for administration of a drug substance |
| 12/08/2004 | EP1484056A1 Sustained release preparations and process for producing the same |
| 12/08/2004 | EP1484055A1 Delivery system with increased bioavailability |
| 12/08/2004 | EP1484053A2 Percutaneously applicable preparation and suppository containing an antidementia medicament |
| 12/08/2004 | EP1484033A1 Liquid polymeric compositions for controlled release of bioactive substances |
| 12/08/2004 | EP1483579A2 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| 12/08/2004 | EP1483374A2 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vivo |
| 12/08/2004 | EP1483313A1 Polymer composite with internally distributed deposition matter |
| 12/08/2004 | EP1483290A2 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments |
| 12/08/2004 | EP1483277A2 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| 12/08/2004 | EP1482988A1 METHOD OF RADIO−LABELLING BIOMOLECULES |
| 12/08/2004 | EP1482982A1 Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof |
| 12/08/2004 | EP1482981A1 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy |
| 12/08/2004 | EP1482980A1 Prostaglandin composition for the treatment of erectile dysfunction |
| 12/08/2004 | EP1482979A1 Enhanced feeding and growth rates of aquatic animals fed an astaxanthin product derived from marigold extract |